Lam Research Corporation
$383.16B- Market cap
- $385.02B
- Debt
- +$3.72B
- Cash
- −$5.58B
Capital structure 99% equity / 1% debt · EV / Revenue 16.49x · EV / EBITDA 43.55x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2026 ·
Decision snapshot: LRCX stock price vs DOCS: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at DOCS's multiple
Needs DOCS P/E.
Implied fair value · at LRCX's multiple
Metric by metric
Price unavailable
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: LRCX FY 2026 (ended Jun 28, 2026) · DOCS FY 2026 (ended Mar 31, 2026). Fiscal years are not aligned.
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 99% equity / 1% debt · EV / Revenue 16.49x · EV / EBITDA 43.55x
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
LAM RESEARCH CORPORATION · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Doximity, Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.30x
0.05x
Net debt / EBITDA
Leverage against operating earnings
-0.21x
-0.64x
Cash and equivalents
Liquid reserves on the balance sheet
$5.58B
$219.18M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Applied Materials, Inc.
LRCX vs AMAT
KLA CORP
LRCX vs KLAC
ASML HOLDING NV
LRCX vs ASML
TERADYNE, INC
LRCX vs TER
ENTEGRIS INC
LRCX vs ENTG
HEALTHEQUITY, INC.
LRCX vs HQY
Teladoc Health, Inc.
LRCX vs TDOC
Hims & Hers Health, Inc.
LRCX vs HIMS
GoodRx Holdings, Inc.
LRCX vs GDRX
$3.72B
$44.32M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.